Updates in RA, PsA, and Biosimilars

Slides:

Advertisements

Similar presentations

Save The Date! Fatigue and Arthritis Wednesday 13 th April 2016 Holiday Inn-Southampton Free Health Care Professional Delegate Places Book Early Signed_________________.

Advertisements

Clinical Trials in IBD.

Psoriatic Arthritis.

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Why Gene Therapy for Hemophilia?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Summary of TB cases across indications and trial periods

Effective Management of Psoriatic Arthritis: Tailoring Treatments

Clinical Developments in Inflammatory Arthritis 2017

Introducing JAK Inhibitors in Rheumatoid Arthritis

Diagnosing Rheumatoid Arthritis Early

Does One Size Fit All in Obesity Management?

T2T Guidelines Promote Shared Decision-Making

Understanding Biologics

Part 1: Disease Activity Measures

Biosimilars in RA: A Blessing or a Curse?

Expert Insights on Psoriatic Arthritis From Washington, DC

Novel Small Molecule Therapies in Rheumatoid Arthritis

Managing RA: Telepartnership Between PCP and Rheumatologist

IL-17 Inhibitors in the Management of Psoriatic Disease

Minding the Gap Rheumatoid Arthritis Advances From London 2016

GLP-1 Receptor Agonists: How Early Is Appropriate?

The Evolving Role of Immunotherapy in NSCLC

What Is a Biosimilar?. Biosimilar Application in RA Clinical Practice: Current Knowledge and New Data

Precision Management of RA and Comorbidities

Clinical Updates in RA: New Developments and Insights From Washington

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

New Pathways in Lipid Care

Team-Based Perspectives on Successful Approaches in Treating Obesity

Contemporary Issues in Psoriasis Care: A Call to Action

Is RA Treatment Addressing the Real Needs of Patients?

Next-Gen Psoriasis Therapies:

Biosimilars in Hematologic Oncology

Evolving Treatment Landscape for PsA

Biotherapeutics.

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

Advancing the Treatment of IBD With Biologics

Comorbidities in RA and PsA

When Is Biologic Therapy Appropriate for HS?

Improving Outcomes in Psoriatic Arthritis

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.

Best Clinical Pearls in Hidradenitis Suppurativa:

Advances in Rheumatoid Arthritis Management

Advancing Patient Care in RA

Guide to Atopic Dermatitis

Management of Systemic Lupus Erythematosus

Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges

Patient-Centered Management in BRAF-Positive Metastatic Melanoma

Ask the Psoriasis Expert

Patient Questions and Expert Answers in Psoriasis:

Severe Asthma and Comorbidities

Optimizing Joint Health in Hemophilia

Critical Decision Points in Insomnia

Application of Biologics in IBD:

Update on the Management of Atopic Dermatitis

Essential Updates for PsA: A Complex Disease to Manage

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

A Primer on Biosimilars

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Optimizing Treatment of Refractory Gout

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Rheumatoid Arthritis.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Biosimilars in Immune-Related Diseases

Psoriatic Arthritis.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Updates in RA, PsA, and Biosimilars

What's New in Rheumatoid Arthritis?

What's New in RA Therapies?

JAK Inhibitors for RA Educating Patients on New Agents

Patient Education and Counseling on New Agents in RA

Patient Education Lifestyle Modification for Patients With RA

Helping Patients With Cost of Medications

Assessing Patients' Quality of Life

What's New in Psoriatic Arthritis?

Advances in Pharmacologic Therapies in Psoriatic Arthritis

Choosing the Appropriate Agent for Patients

Education and Counseling on PsA

Managing PsA

Additional Comorbidities in Patients With PsA

Monitoring Disease Activity

Concluding Remarks

Biosimilars in Rheumatologic Diseases

What Are Biosimilars?

How Do Biosimilars Compare With the Original Biologic?

Safety and Immunogenicity of Biosimilars Compared With Biologics

Biosimilars Are Not the Same as Generics

Biosimilars in Rheumatology

Educating Patients on Biosimilars

Introducing Biosimilars to Patients

Abbreviations